BETA
Manufacturer of SmartShot devices for subchondral bone access during cartilage-repair procedures.
Marrow Access Technologies develops instruments for marrow stimulation in cartilage-repair procedures. Its SmartShot family creates small channels in subchondral bone, with an ankle-specific version designed for access to difficult cartilage lesions.
The company identifies Joseph Saladino as CEO, board chair and co-founder, Trevor Laughlin as engineering and operations leader, and Jason Koh as Chief Medical Officer and co-founder. Its intended professional audience spans sports-medicine and foot-and-ankle surgeons.
Device records identify SmartShot Ankle as a device exempt from premarket submission. That listing is distinct from a 510(k) clearance. Company comparisons with traditional microfracture include bench and preclinical findings; these should not be converted into claims of superior patient outcomes without appropriate clinical evidence.
The reviewed SmartShot Ankle device record identifies exemption from premarket submission. This is not a 510(k) clearance or a finding that every SmartShot-related product has identical regulatory status. Exemption is not FDA approval; intended use, labeling and applicable exemption limitations still govern marketing. [8][1][9][11][2]
No matching FDA recall event was identified in the completed company/applicant, linked-identifier and product-name searches. [6][4]
Latest recorded source review: 2026-10-20.
Documented commercial product families.
Device for creating channels in subchondral bone during marrow-stimulation procedures. [8][1][9]
Exemption documentedCommercially offered; exact model and country availability should be confirmed with the manufacturer.
Current commercialization centers on marrow-access instrumentation and ankle-specific surgical access. Comparative bench findings do not establish superior clinical healing. [8][10]
Accessed 10/29/2026